June 10, 2019
Stories this photo appears in:
The $40M Would Convert Into Shares At 90% of IPO Price
La Jolla-based Inhibrx is prepping for a public debut. Two weeks after raising $40 million, the company in early June filed for an initial public offering to advance three cancer drugs in clinical trials — and other preclinical programs, including an antibiotic.